Breaking News Instant updates and real-time market news.

TEVA

Teva

$18.59

-2.01 (-9.76%)

, VRX

Ticker changed BHC

$15.37

0.24 (1.59%)

08:55
08/08/17
08/08
08:55
08/08/17
08:55

Notable open interest changes for August 8th

Monday's total option volume of 11.8 million contracts resulted in net open interest growth of 2.43 million calls and 2.32 million puts. Teva (TEVA), Valeant (VRX), Apple (AAPL) and Micron (MU) saw the greatest growth. Top five new positions opened include 23k Procter & Gamble (PG) Oct-17 97.5 calls, 20k J C Penney (JCP) 8/11 weekly 5.5 calls, 18k J C Penney (JCP) Aug-17 5.5 puts, 18k Teva (TEVA) Sep-17 15 puts and 17k Qualcomm (QCOM) Sep-17 55 calls.

TEVA

Teva

$18.59

-2.01 (-9.76%)

VRX

Ticker changed BHC

$15.37

0.24 (1.59%)

AAPL

Apple

$158.81

2.42 (1.55%)

MU

Micron

$28.59

0.67 (2.40%)

  • 08

    Aug

  • 24

    Aug

  • 29

    Aug

  • 30

    Aug

  • 06

    Sep

TEVA Teva
$18.59

-2.01 (-9.76%)

08/07/17
MSCO
08/07/17
DOWNGRADE
Target $16
MSCO
Teva downgraded to Underweight, bear case target $9 at Morgan Stanley
As previously reported, Morgan Stanley downgraded Teva to Underweight from Equal Weight and cut its price target to $16 from $36. Analyst David Risinger said he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. He expects core business generic headwinds and Copaxone generic competition to pressure Teva's long-term earnings power and cut his 2017 earnings estimate to $1.24 from $1.55, 2018 earnings estimate to $4.14 from $4.56, and 2019 earnings estimate to $3.79 from $4.50. Risinger's bear case price target on Teva is $9, which assumes much more severe Copaxone erosion and generic business downside.
08/07/17
MSCO
08/07/17
DOWNGRADE
MSCO
Underweight
Teva downgraded to Underweight from Equal Weight at Morgan Stanley
08/04/17
08/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fluor (FLR) was downgraded to Hold from Buy at Deutsche Bank and to Neutral from Buy at DA Davidson. 2. Teva (TEVA) was downgraded to Market Perform from Outperform at Cowen, to Neutral from Outperform at Credit Suisse, and to Underperform from Outperform at RBC Capital. 3. Ford (F) downgraded to Neutral from Buy at Nomura Instinet with analyst Anindya Das citing uncertainties surrounding North America and European growth. 4. Avon Products (AVP) downgraded to Hold from Buy at Deutsche Bank with analyst Faiza Alwy saying the Chief Executive Officer change suggests that a business recovery, should there be one, is more than 12 months away. 5. CommScope (COMM) was downgraded to Hold from Buy at Cross Research, to Neutral from Buy at Longbow, and to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
08/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. 2. Cummins (CMI) downgraded to Buy from Conviction Buy at Goldman Sachs. 3. RE/MAX Holdings (RMAX) downgraded to Equal Weight from Overweight at Stephens. 4. Intrepid Potash (IPI) downgraded to Sell from Neutral at UBS with analyst John Roberts saying that while bankruptcy risk has been "significantly reduced" since the share count was increased 60% with the March secondary, he remains concerned about the lack of long term growth in non-core income and "still depressed" core potash related income. Roberts cites valuation for his downgrade and raised his price target for Intrepid Potash shares to $2.50 from $2.00. 5. Eaton (ETN) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VRX Ticker changed BHC
$15.37

0.24 (1.59%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.
AAPL Apple
$158.81

2.42 (1.55%)

08/02/17
NEED
08/02/17
NO CHANGE
Target $175
NEED
Buy
Apple price target raised to $175 from $165 at Needham
Needham analyst Laura Martin raised her price target for Apple to $175 from $165 following Q3 results. The analyst reiterates a Buy rating on the shares and says Apple remains her top stock pick for 2017 owing to strategic position, EPS upside, falling risks, catalysts, and valuation.
08/03/17
BMOC
08/03/17
NO CHANGE
BMOC
Criteo should be bought on weakness, says BMO Capital
BMO Capital analyst Daniel Salmon says Criteo's (CRTO) stock declined on the company's "cautious comments" about Apple's (AAPL) "intelligent tracking prevention" rollout in September. The analyst doesn't expect Apple's initiative to be a "material disruption" for Criteo and he believes that Criteo's "network effect continues to build." He keeps a $70 price target and an Outperform rating on the shares.
08/04/17
FBCO
08/04/17
UPGRADE
Target $11.3
FBCO
Outperform
Himax upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Jerry Su upgraded Himax to Outperform from Neutral and raised his 2018 and 2019 estimates for the company citing expectations for better DDI sales and his belief that its Diffractive Optical Element, or DOE, will be used in Apple's (AAPL) upcoming iPhone. He raised his price target on Himax shares to $11.30 from $8.70.
08/03/17
OPCO
08/03/17
NO CHANGE
OPCO
Perform
Cirrus Logic guidance suggests no major iPhone 8 content growth,says Oppenheimer
Oppenheimer analyst Rick Schafer notes that Cirrus Logic (CRUS) reported in-line Q1 and says he believes Q2 guidance confirms his view that significant gen/gen content growth in the Apple's (AAPL) iPhone 8 is unlikely. The analyst reiterates a Perform rating on Cirrus Logic's shares.
MU Micron
$28.59

0.67 (2.40%)

08/01/17
SBSH
08/01/17
NO CHANGE
Target $45
SBSH
Buy
Micron recent pullback a buying opportunity, says Citi
Citi analyst Christopher Danely attributes the 12% pullback in shares of Micron over the past week to fears of memory overcapacity. Micron has traded down because of fears of a DRAM downturn driven by an increase in DRAM capital expenditures, Danely tells investors in a research note. DRAM capex in 2017 has increased from $8.9B to $9.9B year-over-year, but it is still not enough to cause a downturn, the analyst contends. He reiterates a Buy rating on Micron with a $45 price target.
07/31/17
WELS
07/31/17
NO CHANGE
WELS
Wells Fargo downgrades Semiconductor sector to Market Weight
Wells Fargo analyst David Wong downgraded the Semiconductor sector to Market Weight from Overweight. Recent earnings reports from chip companies suggest that year-over-year growth will likely plateau or perhaps even decelerate over the next few months, Wong tells investors in a research note. He believes many chip stocks now have "elevated multiples" off calendar 2018 earnings estimates. Wong still sees good investment opportunities in some specific stocks, however, and reiterates Outperform ratings on Intel (INTC), Qualcomm (QCOM), Micron (MU), AMD (AMD), Skyworks (SWKS) and Microsemi (MSCC).
07/27/17
STFL
07/27/17
NO CHANGE
STFL
Micron has positive read through from Samsung comments, says Stifel
Stifel analyst Kevin E. Cassidy reports that Samsung indicated that conditions for memory suppliers would be favorable at least through the end of the year. Additionally, Cassidy thinks that the company's comments indicate that it is looking to maintain a supply/demand balance. He views Samsung's comments as positive for Micron and says they should alleviate the fears of the latter company's investors. The analyst keeps a Buy rating on Micron.
07/26/17
SBSH
07/26/17
NO CHANGE
Target $45
SBSH
Buy
Micron selloff yesterday a buying opportunity, says Citi
Citi analyst Christopher Danely recommends using the selloff yesterday in shares of Micron Technology as a buying opportunity. Fears of weaker DRAM pricing moved the stock lower after Hynix announced it will increase DRAM capital expenditures and expects supply tightness in DRAM to ease in the second half of 2017, Danely tells investors in a research note. The analyst does not believe this level of capacity increase is enough to materially weaken the DRAM market. He keeps a Buy rating on Micron shares with a $45 price target.

TODAY'S FREE FLY STORIES

GPRO

GoPro

$6.46

-0.05 (-0.77%)

, CMCSA

Comcast

$37.91

0.1 (0.26%)

09:05
09/24/18
09/24
09:05
09/24/18
09:05
Periodicals
Tile names GoPro vet CJ Prober CEO, adds Comcast as investor, TechCrunch says »

Tile is appointing CJ…

GPRO

GoPro

$6.46

-0.05 (-0.77%)

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNBX

Cannabics Pharmaceuticals

$0.00

(0.00%)

09:04
09/24/18
09/24
09:04
09/24/18
09:04
Syndicate
Cannabics Pharmaceuticals raises $7.5M in a registered direct offering »

Cannabics Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$107.62

-0.32 (-0.30%)

09:03
09/24/18
09/24
09:03
09/24/18
09:03
Recommendations
Quest Diagnostics analyst commentary  »

Quest Diagnostics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALPMY

Astellas Pharma

$0.00

(0.00%)

, PFE

Pfizer

$44.06

0.3 (0.69%)

09:02
09/24/18
09/24
09:02
09/24/18
09:02
Hot Stocks
Astellas Pharma receives positive CHMP opinion for Xtandi »

Astellas Pharma announced…

ALPMY

Astellas Pharma

$0.00

(0.00%)

PFE

Pfizer

$44.06

0.3 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 01

    Oct

  • 03

    Oct

  • 03

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 30

    Oct

ALT

Altimmune

$26.03

0.53 (2.08%)

09:02
09/24/18
09/24
09:02
09/24/18
09:02
Syndicate
Altimmune raises $4.9M in a registered direct offering »

Altimmune announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALT

Altimmune

$26.03

0.53 (2.08%)

09:02
09/24/18
09/24
09:02
09/24/18
09:02
Syndicate
Altimmune announces $4.9M registered direct offering of common stock »

Altimmune announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$69.05

0.25 (0.36%)

09:02
09/24/18
09/24
09:02
09/24/18
09:02
Recommendations
Abbott analyst commentary  »

Abbott Mitraclip data a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

09:01
09/24/18
09/24
09:01
09/24/18
09:01
Hot Stocks
Breaking Hot Stocks news story on Sirius XM »

Sirius XM doesn't…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

PDLI

PDL BioPharma

$2.42

-0.02 (-0.82%)

09:01
09/24/18
09/24
09:01
09/24/18
09:01
Hot Stocks
PDL BioPharma announces new $100M share repurchase program »

PDL BioPharma announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$6.15

-1.7 (-21.66%)

09:01
09/24/18
09/24
09:01
09/24/18
09:01
Syndicate
New Age Beverages to offer up to $50M in shares via 'At the Market' offering »

New Age Beverages…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

, P

Pandora

$9.08

-0.31 (-3.30%)

09:01
09/24/18
09/24
09:01
09/24/18
09:01
Hot Stocks
Sirius XM says company, Pandora to pay royalties approaching $2B in 2019 »

Sirius XM (SIRI) says…

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

P

Pandora

$9.08

-0.31 (-3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

RDC

Rowan Companies

$18.02

0.54 (3.09%)

08:59
09/24/18
09/24
08:59
09/24/18
08:59
Upgrade
Rowan Companies rating change  »

Rowan Companies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SEAS

SeaWorld

$30.10

-0.5 (-1.63%)

08:58
09/24/18
09/24
08:58
09/24/18
08:58
Recommendations
SeaWorld analyst commentary  »

SeaWorld price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTRX

Lantronix

$4.14

-0.12 (-2.82%)

08:58
09/24/18
09/24
08:58
09/24/18
08:58
Recommendations
Lantronix analyst commentary  »

Lantronix shares can see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AAPL

Apple

$217.65

-2.35 (-1.07%)

08:57
09/24/18
09/24
08:57
09/24/18
08:57
Recommendations
Apple analyst commentary  »

Rosenblatt says Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TEUM

Pareteum

$2.80

-0.03 (-1.06%)

08:55
09/24/18
09/24
08:55
09/24/18
08:55
Initiation
Pareteum initiated  »

Pareteum initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTV

Fortive

$86.97

-0.45 (-0.51%)

, AAPL

Apple

$217.65

-2.35 (-1.07%)

08:55
09/24/18
09/24
08:55
09/24/18
08:55
Options
Notable open interest changes for September 24th »

Friday's total…

FTV

Fortive

$86.97

-0.45 (-0.51%)

AAPL

Apple

$217.65

-2.35 (-1.07%)

AMD

AMD

$31.01

-0.17 (-0.55%)

MU

Micron

$44.70

-1.36 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

08:55
09/24/18
09/24
08:55
09/24/18
08:55
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

, P

Pandora

$9.08

-0.31 (-3.30%)

08:54
09/24/18
09/24
08:54
09/24/18
08:54
Hot Stocks
Breaking Hot Stocks news story on Sirius XM, Pandora, Spotify »

Sirius XM sees taking…

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

P

Pandora

$9.08

-0.31 (-3.30%)

SPOT

Spotify

$175.06

2.38 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

UNFI

United Natural Foods

$31.02

-2.81 (-8.31%)

, SVU

Supervalu

$32.24

0.02 (0.06%)

08:52
09/24/18
09/24
08:52
09/24/18
08:52
Recommendations
United Natural Foods, Supervalu analyst commentary  »

United Natural Foods…

UNFI

United Natural Foods

$31.02

-2.81 (-8.31%)

SVU

Supervalu

$32.24

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

MU

Micron

$44.70

-1.36 (-2.95%)

, INTC

Intel

$46.64

-0.56 (-1.19%)

08:52
09/24/18
09/24
08:52
09/24/18
08:52
Recommendations
Micron, Intel analyst commentary  »

Micron price target…

MU

Micron

$44.70

-1.36 (-2.95%)

INTC

Intel

$46.64

-0.56 (-1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 22

    Oct

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

, P

Pandora

$9.08

-0.31 (-3.30%)

08:50
09/24/18
09/24
08:50
09/24/18
08:50
Hot Stocks
Sirius XM: Pandora talks the 'worst kept secret of a courtship' »

Sirius XM (SIRI) says it…

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

P

Pandora

$9.08

-0.31 (-3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

08:50
09/24/18
09/24
08:50
09/24/18
08:50
Conference/Events
CLSA energy analysts to hold an analyst/industry conference call »

Head of Sustainable…

HMNY

Helios and Matheson

$0.01

-0.001 (-6.71%)

08:49
09/24/18
09/24
08:49
09/24/18
08:49
Hot Stocks
MoviePass Films co-acquires 'Monsters and Men', 'Border' with NEON »

MoviePass Films, a film…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

, P

Pandora

$9.08

-0.31 (-3.30%)

08:48
09/24/18
09/24
08:48
09/24/18
08:48
Hot Stocks
Breaking Hot Stocks news story on Sirius XM, Pandora »

Sirius XM says let…

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

P

Pandora

$9.08

-0.31 (-3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.